Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine Maintenance in Adolescent Bipolar Spectrum Disorders
NCT00252226Phase 3Completed
- Sponsor
- Mood Disorders Center of Ottawa
- Start
- Jun 2004
- Primary completion
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of quetiapine in bipolar spectrum disorder (BSD), sponsored by Mood Disorders Center of Ottawa. Primary endpoint: Proportion of treated study patients maintained on monotherapy at 48 weeks. Started Jun 2004; status: completed.
02
Drugs
quetiapine
03
Conditions
bipolar spectrum disorder (BSD)
Beyond the preview
Go deeper on NCT00252226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00252226.